This Family Office Acquired $148 Million of Karman Stock as Shares Tripled Since February IPO

Schusterman Interests disclosed a new 13F position of nearly 2.1 million Karman Holdings (NYSE:KRMN) shares valued at $148 million as of Sept. 30, representing approximately 33.8% of the fund's reported 13F assets and making Karman its largest equity holding. Karman, an aerospace and defense supplier that IPO'd in February at $22, closed recently at $67.03, with a market cap of $7.97 billion, TTM revenue of $428.2 million and TTM net income of $11.3 million. The concentrated family‑office bet — disclosed Nov. 14 — signals institutional underwriting of an early‑stage defense supplier and may influence sentiment toward newly listed industrial and med‑tech names.

Analysis

Market structure: A 33.8% concentration by Schusterman in KRMN (2.1M shares, $148M) removes meaningful free float and can mechanically tighten liquidity and bid/offer spreads near-term, supporting price discovery; incumbents in mission-critical aerospace (large primes and specialty suppliers) benefit from increased attention and higher multiples while pure-play small suppliers without program diversification risk losing relative investor flows. Competitive dynamics: Karman’s $7.97B market cap on $428M revenue (P/S ≈ 18.6) implies market pricing for sustained high growth; if KRMN converts backlog into multi-year bookings and expands gross margins by 300–500bp over 12–24 months, it can gain pricing power—failure to do so will produce sharp multiple compression. Risk assessment: Tail risks include sudden program cancellations, export/regulatory restrictions, or lock-up/insider selling (typical 6–12 month window) that could drive a 30–50% drawdown; near-term (days/weeks) risk centers on liquidity shocks, short-to-medium term (months) on contract awards and quarterly bookings, and long-term (years) on integration scale and margin recovery. Trade implications: Favor a measured long exposure to KRMN with explicit hedges—use collars or long-dated puts to limit downside; watch catalysts (quarterly results, DOD contract announcements, FY budget votes) in next 30–90 days to add/sell, and consider shorting weaker IPO peers or using sector hedges (defense small-cap basket) if signs of re-rating stall.

Key Decisions for Investors

• Establish a 1–2% portfolio long position in KRMN (NYSE:KRMN) with a 6–12 month horizon; set automated reduce or hedge if price falls to $50 (≈ -25%) and plan to take partial profits if price exceeds $95 (≈ +42%) on confirmed margin expansion or large contract wins.
• Buy a 9-month protective put (≈25–30% OTM or a 25-delta) for ~50–75% of the position size to cap tail risk; alternatively implement a 9-month collar (sell 10% OTM calls) to finance the hedge if yield generation is needed.
• Sell 40–60% of the position as covered calls 6–8 weeks out ~10% OTM to harvest premium while retaining upside optionality; roll monthly if implied volatility compresses but preserve downside hedge.
• Prepare a relative-value pair: long KRMN (1.5%) vs short HTFL (0.5–0.75%) or a small-cap aerospace basket if HTFL not available—short leg to size portfolio beta and profit from IPO/med-tech re-rating risk over the next 3–6 months.
• Only scale >3% into KRMN after one of these catalysts within 90 days: 1) backlog growth >20% YoY or 2) new multi-year DOD/commercial award disclosed, or 3) sustained gross margin improvement >200bp QoQ; otherwise keep exposure limited and hedged.